WHO ICTRP trial
Clot regression effects of rivaroxaban in treatment of venous thromboembolism in…
JPRN-jRCTs051180077 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs051180077 |
|---|---|
| Public title | Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients. |
| Scientific title | Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients. - Clot regression in cancer VTE patients |
| Primary sponsor | Matoba Satoaki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Conditions | Venous thromboembolism |
| Interventions | VTE patients receive the NHI-covered standard rivaroxaban treatment (30 mg/day for 3 weeks after initiation of treatment, followed by 15 mg/day) |
| Registration date | Feb 27, 2019 |
| Target size | 40 |
| Secondary IDs | UMIN000027793 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: